27 Street Clair Avenue East
PO Box 305
Toronto, ON M4T 2M5
Canada
647-428-7031
https://www.archbiopartners.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Andrew Bishop CFA | CFO & Director | N/A | N/A | 1966 |
Mr. Richard Gabriel Muruve | Co-Founder, CEO, President & Director | 112,5k | N/A | 1971 |
Dr. Justin MacDonald Ph.D. | Co-Founder & Principal Scientist | N/A | N/A | N/A |
Dr. Paul Beck | Co-Founder & Principal Scientist | N/A | N/A | N/A |
Mr. Aaron Benson | Director of Communications | N/A | N/A | N/A |
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals. Arch Biopartners Inc. is based in Toronto, Canada.
Arch Biopartners Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.